Crosstalk between ER stress and immunogenic cell death |
| |
Authors: | Oliver Kepp Laurie Menger Erika Vacchelli Clara Locher Sandy Adjemian Takahiro Yamazaki Isabelle Martins Abdul Qader Sukkurwala Michael Michaud Laura Senovilla Lorenzo Galluzzi Guido Kroemer Laurence Zitvogel |
| |
Affiliation: | 1. Université Paris-Sud/Paris XI, Le Kremlin-Bicêtre, France;2. INSERM, U848, Villejuif, France;3. Institut Gustave Roussy, Villejuif, France;4. INSERM, U1015, Villejuif, France;5. Center of Clinical Investigations CBT507, Institut Gustave Roussy, Villejuif, France;6. Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France;7. Equipe 11 labellisée Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France;8. Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, France;9. Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France |
| |
Abstract: | Preclinical and clinical findings suggest that tumor-specific immune responses may be responsible – at least in part – for the clinical success of therapeutic regimens that rely on immunogenic cell death (ICD) inducers, including anthracyclines and oxaliplatin. The molecular pathways whereby some, but not all, cytotoxic agents promote bona fide ICD remain to be fully elucidated. Nevertheless, a central role for the endoplasmic reticulum (ER) stress response has been revealed in all scenarios of ICD described thus far. Hence, components of the ER stress machinery may constitute clinically relevant druggable targets for the induction of ICD. In this review, we will summarize recent findings in the field of ICD research with a special focus on ER stress mechanisms and their implication for cancer therapy. |
| |
Keywords: | Anthracyclines Apoptosis ATP Calcium Calreticulin PERK |
本文献已被 ScienceDirect 等数据库收录! |
|